Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study

Journal of Clinical Oncology

Volumn 33, Issue 33, 2015, Pages 3938-3944

  Solin, Lawrence J ^a   Gray, Robert ^c   Hughes, Lorie L ^f   Wood, William C ^g   Lowen, Mary Ann ^e   Badve, Sunil S ^h   Baehner, Frederick L ⁱ   Ingle, James N ^j   Perez, Edith A ^k   Recht, Abram ^d   Sparano, Joseph A ^l   Davidson, Nancy E ^b  

^a EINSTEIN MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BAYSTATE MEDICAL CENTER   (United States)

^f Gordon Hospital   (United States)

^g EMORY UNIVERSITY   (United States)

^h INDIANA UNIVERSITY   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j MAYO CLINIC   (United States)

^k MAYO CLINIC   (United States)

^l MONTEFIORE MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST DISEASE; CANCER PATIENT; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; IPSILATERAL BREAST EVENT; MAJOR CLINICAL STUDY; PARTIAL MASTECTOMY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; SURGICAL RISK; TREATMENT OUTCOME; TUMOR VOLUME; ADVERSE EFFECTS; BREAST NEOPLASMS; CANCER STAGING; CARCINOMA, INTRADUCTAL, NONINFILTRATING; COMPARATIVE STUDY; EPIDEMIOLOGY; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE; TIME FACTOR; TUMOR INVASION; TUMOR RECURRENCE;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL RATE; TAMOXIFEN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84948448538     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.60.8588     Document Type: Article

References (33)

1. Allegra CJ, Aberle DR, Ganschow P, et al: National Institutes of Health State-of-the-Science Conference statement: Diagnosis and management of ductal carcinoma in situ September 22-24, 2009. J Natl Cancer Inst 102:161-169, 2010
2. Burstein HJ, Polyak K, Wong J.S., et al: Ductal carcinoma in situ of the breast. N Engl J Med 350:1430-1441, 2004
3. Schwartz GF, Solin LJ, Olivotto I.A., et al: Consensus conference on the treatment of in situ ductal carcinoma of the breast, April 22-25, 1999. Cancer 88:946-954, 2000
4. Zujewski JA, Harlan LC, Morrell D.M., et al: Ductal carcinoma in situ: Trends in treatment over time in the US. Breast Cancer Res Treat 127:251-257, 2011
5. Dodwell D, Clements K, Lawrence G., et al: Radiotherapy following breast-conserving surgery for screen-detected ductal carcinoma in situ: Indications and utilisation in the UK - Interim findings from the Sloane Project. Br J Cancer 97:725-729, 2007
6. Baxter NN, Virnig BA, Durham S.B., et al: Trends in the treatment of ductal carcinoma in situ of the breast. J Natl Cancer Inst 96:443-448, 2004
7. Smith GL, Smith BD, Haffty BG: Rationalization and regionalization of treatment for ductal carcinoma in situ of the breast. Int J Radiat Oncol Biol Phys 65:1397-1403, 2006
8. Fisher B, Dignam J, Wolmark N., et al: Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol 16:441-452, 1998
9. Fisher B, Land S, Mamounas E., et al: Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28: 400-418, 2001
10. Wapnir IL, Dignam JJ, Fisher B, et al: Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS. J Natl Cancer Inst 103:478-488, 2011
11. Donker M, Litière S, Werutsky G., et al: Breastconserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial. J Clin Oncol 31:4054-4059, 2013
12. Bijker N, Meijnen P, Peterse J.L., et al: Breastconserving treatment with or without radiotherapy in ductal carcinoma-in-situ: Ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853 - A study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 24:3381-3387, 2006
13. Bijker N, Peterse JL, Duchateau L, et al: Risk factors for recurrence and metastasis after breastconserving therapy for ductal carcinoma-in-situ: Analysis of European Organization for Research and Treatment of Cancer Trial 10853. J Clin Oncol 19: 2263-2271, 2001
14. Cuzick J, Sestak I, Pinder S.E., et al: Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: Long-term results from the UK/ANZ DCIS trial. Lancet Oncol 12:21-29, 2011
15. Warnberg F, Garmo H, Emdin S., et al: Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS trial. J Clin Oncol 32:3613-3618, 2014
16. McCormick B, Winter K, Hudis C., et al: RTOG 9804: A prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation. J Clin Oncol 33:709-715, 2015
17. Correa C, McGale P, Taylor C., et al: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 41:162-177, 2010
18. Fisher B, Dignam J, Wolmark N., et al: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 353:1993-2000, 1999
19. Allred DC, Anderson SJ, Paik S, et al: Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ: A study based on NSABP protocol B-24. J Clin Oncol 30:1268-1273, 2012
20. Hughes LL, Wang M, Page D.L., et al: Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 27:5319-5324, 2009
21. Solin LJ, Gray R, Baehner F.L., et al: A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast. J Natl Cancer Inst 105:701-710, 2013
22. Page DL, Anderson TJ, Rogers LW: Carcinoma in situ (CIS), in Page DL, Anderson TJ (eds): Diagnostic Histopathology of the Breast (ed 1). Edinburgh, UK, Churchill Livingstone, 1987, pp 157-192
23. Lester SC, Bose S, Chen Y.Y., et al: Protocol for the examination of specimens from patients with ductal carcinoma in situ of the breast. Arch Pathol Lab Med 133:15-25, 2009
24. Badve SS, Gray RJ, Baehner F.L., et al: Correlation between the DCIS score and traditional clinicopathologic features in the prospectively designed E5194 clinical validation study. J Clin Oncol 30:50s, 2012 (abstr 1005)
25. Silverstein MJ, Lagios MD Choosing treatment for patients with ductal carcinoma in situ: Fine tuning the University of Southern California/Van Nuys Prognostic Index. J Natl Cancer Inst Monogr 41:193-196, 2010
26. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf
27. Moran MS, Bai HX, Harris E.E., et al: ACR appropriateness criteria ductal carcinoma in situ. Breast J 18:8-15, 2012
28. Wong JS, Chen YH, Gadd M.A., et al: Eight-year update of a prospective study of wide excision alone for small lowor intermediate-grade ductal carcinoma in situ (DCIS). Breast Cancer Res Treat 143:343-350, 2014
29. Rakovitch E, Nofech-Mozes S, Hanna W., et al: A population-based validation study of the DCIS Score predicting recurrence risk in individuals treated by breast-conserving surgery alone. Breast Cancer Res Treat 152:389-398, 2015
30. Kerlikowske K, Molinaro AM, Gauthier M.L., et al: Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis. J Natl Cancer Inst 102:627-637, 2010
31. Rakovitch E, Nofech-Mozes S, Hanna W., et al: HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer 106:1160-1165, 2012
32. Williams KE, Barnes NL, Cramer A, et al: Molecular phenotypes of DCIS predict overall and invasive recurrence. Ann Oncol 26:1019-1025, 2015
33. Sakr RA, Andrade VP, Chandarlapaty S, et al: Molecular predictors for type of recurrence following conservative treatment for DCIS. Cancer Res 72, 2012 (abstr PD04-05)